

19 March 2018,

The CALYM Carnot Institute and the Institut Roche, Partners to Accelerate Together Research against Lymphoma!

At the end of December 2017, a framework contract was signed between CALYM and the Institut Roche to define the terms of a joint call for projects for the development of preclinical and translational research partnerships in onco-hematology.

The CALYM Carnot institute aims at accelerating innovation and its transfer in the lymphoma field, particularly in the translational phase. To transform its discoveries of basic research into clinical applications for the patient, the institute benefits from the financial support of the French government (National Research Agency) and relies on public-private partnerships it develops with industry and other research and technological organizations.

It is in this context that CALYM has come closer to the Institut Roche which missions are to lead and develop strategic projects of basic or translational research in partnership with the French research teams of excellence.

A joint call for projects was launched for a global budget of € 400,000 over two years. Selected projects must make it possible to build a biological rationale by providing proof of concept, by elucidating the mode of action of drug candidates or with appropriate and effective preclinical studies. Ultimately, the goal is to develop new targeted immunotherapy treatments for lymphoma patients.



About the Institut Roche

The Institut Roche is an accelerator of scientific and biomedical innovation at the service of the patient. As a collaborative and multidisciplinary research structure, the Institut Roche's ambition is to rapidly transform basic research discoveries into clinical applications for the patient. The Institut Roche builds and promotes high-level scientific partnerships with French academic teams, thus contributing to the discovery of therapeutic innovations. It positions itself as the privileged interface between the French scientific community and the research centers of Roche Group, particularly pRED (Pharma Research Early Development) and gRED (Genentech Research Early Development), as well as the medical research teams of Roche France.

About the CALYM Carnot Institute

The CALYM Carnot institute offers a unique R&D approach in lymphoma treatments and diagnostics, spanning from new target identification to large international Phase III clinical trials and beyond. CALYM brings together 15 entities with complementary expertise in preclinical, translational and clinical lymphoma research: the Lymphoma Study Association (LYSA), a cooperative group, international leader of lymphoma research with 500 members, the Lymphoma Academic Research Organisation (LYSARC), the largest academic clinical organization in Europe in this field and 13 public preclinical research teams of excellence based at universities and hospitals across France. This set, without international equivalent, aims, in partnership with companies, at accelerating innovation and its transfer in the therapeutic, diagnostic and imaging lymphoma sectors in response to unmet medical needs identified by healthcare professionals.

www.calym.org